BioCentury
ARTICLE | Clinical News

MultiStem: Additional Phase II data

February 22, 2016 8:00 AM UTC

Additional data from 126 patients in a double-blind, U.S. and U.K. Phase II trial showed that a single dose of IV MultiStem given 24-48 hours following stroke improved the proportion of patients with an mRS score of <=1 point, an NIHSS score of <=1 point and a BI of >=95 points at 1 year vs. placebo (23.1% vs. 8.2%, p=0.02). In 92 patients who received MultiStem within 36 hours following stroke, 29% achieved an mRS score of <=1 point, an NIHSS score of <=1 point and a BI of >=95 points at 1 year vs. placebo (p<0.01). Additionally, 61.5% of patients who received MultiStem within 48 hours following stroke and 67.7% of patients who received MultiStem within 36 hours following stroke achieved a BI of >=95 points at 1 year vs. 44.3% of patients who received placebo (p=0.05 and p=0.03, respectively). Furthermore, patients who received MultiStem within 36 hours following stroke had an average of 2.9 fewer average hospitalization days and an 11.4% lower incidence of death or life threatening adverse events vs. placebo. ...